Bristol Myers Financials

BMY Stock  USD 54.23  0.98  1.84%   
Based on the key indicators related to Bristol Myers' liquidity, profitability, solvency, and operating efficiency, Bristol Myers Squibb is performing exceptionally good at this time. It has a great probability to report excellent financial results in April. At this time, Bristol Myers' Good Will is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 99.9 B in 2024, whereas Total Stockholder Equity is likely to drop slightly above 15 B in 2024. Key indicators impacting Bristol Myers' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio1.481.4089
Sufficiently Up
Slightly volatile
Operating Income18.1 B17.2 B
Sufficiently Up
Slightly volatile
Current Ratio1.961.4271
Significantly Up
Very volatile
The financial analysis of Bristol Myers is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Bristol Myers includes many different criteria found on its balance sheet. For example, investors should never minimize Bristol Myers' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Bristol Myers' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Bristol Myers.

Cash And Equivalents

10.46 Billion

With this module, you can analyze Bristol financials for your investing period. You should be able to track the changes in Bristol Myers individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past Bristol Myers Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bristol Myers' financial statements are interrelated, with each one affecting the others. For example, an increase in Bristol Myers' assets may result in an increase in income on the income statement.
Evaluating Bristol Myers' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of Bristol Myers' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the Bristol Myers' relative financial performance

Chance Of Distress

Less than 1

 
100  
 
Zero
Very Small
Bristol Myers Squibb has less than 1 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Bristol Myers stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, Bristol Myers' odds of distress score SHOULD NOT be confused with the real chance of Bristol Myers Squibb filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as Bristol is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include Bristol Myers' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in Bristol Myers' official financial statements usually reflect Bristol Myers' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bristol-Myers Squibb. For example, before you start analyzing numbers published by Bristol accountants, it's critical to develop an understanding of what Bristol Myers' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Bristol Myers' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bristol Myers' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bristol Myers' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bristol Myers Squibb. Please utilize our Beneish M Score to check the likelihood of Bristol Myers' management manipulating its earnings.

Bristol Myers Company Summary

Bristol Myers competes with Madrigal Pharmaceuticals, 23Andme Holding, Moleculin Biotech, Equillium, and Mustang Bio. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company was founded in 1887 and is headquartered in New York, New York. Bristol-Myers Squibb operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 32200 people.
Foreign Associate
  Mexico
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNew York Stock Exchange
CIK Number0000014272
ISINUS1101221083
CUSIP110122108
RegionNorth America
LocationNew York; U.S.A
Business AddressRoute 206 Province
SectorPharmaceuticals
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.bms.com
Phone609 252 4621
CurrencyUSD - US Dollar
You should never invest in Bristol Myers without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Bristol Stock, because this is throwing your money away. Analyzing the key information contained in Bristol Myers' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Bristol Myers Key Financial Ratios

Generally speaking, Bristol Myers' financial ratios allow both analysts and investors to convert raw data from Bristol Myers' financial statements into concise, actionable information that can be used to evaluate the performance of Bristol Myers over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Bristol-Myers Squibb reports annually and quarterly.

Bristol Myers Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets129.9B118.5B109.3B96.8B95.2B99.9B
Other Current Liab7.9B10.2B10.1B13.1B11.5B12.1B
Net Debt35.2B37.1B31.6B31.6B30B31.5B
Retained Earnings34.5B21.3B23.8B25.5B28.8B22.0B
Cash12.3B14.5B14.0B9.1B11.5B12.0B
Net Receivables7.7B8.5B12.5B13.9B15.3B16.0B
Good Will22.5B20.5B20.5B21.1B21.2B22.2B
Inventory4.3B2.1B2.1B2.3B2.7B1.9B
Other Current Assets2.0B1.4B1.3B1.6B1.5B1.8B
Total Liab78.2B80.6B73.3B65.7B65.7B69.0B
Total Current Assets29.4B30.2B33.3B27.3B31.8B33.4B
Short Term Debt3.5B2.5B5.1B4.4B3.3B3.4B
Intangible Assets64.0B53.2B42.8B36.4B27.5B28.9B
Accounts Payable2.4B2.7B2.9B3.0B3.3B1.9B
Other Liab15.9B12.3B11.0B7.4B8.5B4.9B
Other Assets4.8B7.3B3.3B2.9B3.3B3.3B
Long Term Debt43.4B48.3B39.6B35.1B36.7B38.5B
Treasury Stock(19.6B)(25.4B)(26.2B)(31.3B)(28.1B)(26.7B)
Net Tangible Assets(34.9B)(36.0B)(28.2B)(25.9B)(23.4B)(22.2B)

Bristol Myers Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Bristol Myers' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Interest Expense656M1.4B1.3B1.2B1.2B1.2B
Total Revenue26.1B42.5B46.4B46.2B45.0B47.3B
Gross Profit18.1B30.7B36.4B36.0B34.3B36.0B
Operating Income5.5B5.1B10.2B10.3B17.2B18.1B
Ebit5.5B5.1B10.2B10.3B9.4B5.1B
Ebitda6.6B14.8B20.2B19.9B19.2B20.1B
Cost Of Revenue8.1B11.8B9.9B10.1B10.7B5.8B
Income Before Tax5.0B(6.9B)8.1B7.7B8.4B4.2B
Net Income3.4B(9.0B)7.0B6.3B8.0B8.4B
Income Tax Expense1.5B2.1B1.1B1.4B400M380M
Research Development6.1B11.1B10.2B9.5B9.3B9.8B
Minority Interest21M20M(20M)(18M)(16.2M)(15.4M)
Tax Provision1.5B2.1B1.1B1.4B322M305.9M
Net Interest Income(656M)(1.4B)(1.3B)(1.2B)(1.1B)(1.2B)
Interest Income69M71M550M1.9B2.1B2.2B

Bristol Myers Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Bristol-Myers Squibb. It measures of how well Bristol is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Bristol Myers brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Bristol had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Bristol Myers has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201920202021202220232024 (projected)
Change To Inventory463M2.7B13M(69M)(751M)(713.5M)
Change In Cash5.9B2.2B(657M)(5.0B)2.2B2.3B
Free Cash Flow7.2B13.3B15.2B11.9B12.7B13.3B
Depreciation1.7B10.4B10.7B10.3B9.8B10.2B
Other Non Cash Items279M9.9B570M955M744M781.2M
Dividends Paid2.7B4.1B4.4B4.6B(4.7B)(4.5B)
Capital Expenditures836M753M973M1.1B1.2B837.5M
Net Income3.5B(9.0B)7.0B6.3B8.0B8.4B
End Period Cash Flow12.8B15.0B14.3B9.3B11.5B12.1B
Change To Netincome(62M)(197M)(748M)(1.1B)(970.2M)(921.7M)
Investments(152M)2.1B1.3B3.0B264M270.6M
Change Receivables752M(646M)(1.1B)(663M)(596.7M)(566.9M)
Net Borrowings17.7B3.9B(6.2B)(5.3B)(6.1B)(5.8B)

Bristol Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myers's current stock value. Our valuation model uses many indicators to compare Bristol Myers value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol Myers competition to find correlations between indicators driving Bristol Myers's intrinsic value. More Info.
Bristol Myers Squibb is number one stock in current liabilities category among related companies. It is rated second in price to earning category among related companies . The ratio of Current Liabilities to Price To Earning for Bristol Myers Squibb is about  322,226,688 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bristol Myers by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bristol Myers' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bristol Myers' earnings, one of the primary drivers of an investment's value.

Bristol-Myers Squibb Systematic Risk

Bristol Myers' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bristol Myers volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Bristol-Myers Squibb correlated with the market. If Beta is less than 0 Bristol Myers generally moves in the opposite direction as compared to the market. If Bristol Myers Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bristol-Myers Squibb is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bristol Myers is generally in the same direction as the market. If Beta > 1 Bristol Myers moves generally in the same direction as, but more than the movement of the benchmark.

About Bristol Myers Financials

What exactly are Bristol Myers Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Bristol Myers' income statement, its balance sheet, and the statement of cash flows. Potential Bristol Myers investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Bristol Myers investors may use each financial statement separately, they are all related. The changes in Bristol Myers's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol Myers's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze Bristol Myers Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Bristol Myers is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Bristol has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Bristol Myers' financials are consistent with your investment objective using the following steps:
  • Review Bristol Myers' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Bristol Myers' liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Bristol Myers' financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Bristol Myers' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

Bristol Myers Thematic Clasifications

Bristol Myers Squibb is part of several thematic ideas from Healthcare to Compulsion. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Bristol Myers Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bristol Myers' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Bristol Myers growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.45

At this time, Bristol Myers' Price Earnings To Growth Ratio is fairly stable compared to the past year.

Bristol Myers March 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Bristol Myers help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bristol Myers Squibb. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bristol Myers Squibb based on widely used predictive technical indicators. In general, we focus on analyzing Bristol Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bristol Myers's daily price indicators and compare them against related drivers.
When determining whether Bristol-Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.09)
Dividend Share
2.31
Earnings Share
3.86
Revenue Per Share
21.753
Quarterly Revenue Growth
0.006
The market value of Bristol-Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.